Abstract
Invasion leading to the formation of metastasis is one of the hallmarks of cancer. Analysis of different human cancers has led to the identification of the PPFIA1 gene encoding the protein liprin-α1, a possible player in cancer. The PPFIA1 gene is amplified in malignant tumors, including about 20% of breast cancers. Also the liprin-α1 protein is found overexpressed in tumors. Liprin-α1 belongs to the liprin family of cytosolic scaffold proteins that includes four liprin-α, two liprin-β members, and liprin-γ/kazrinE. In this review we will discuss the available evidence on the role of different members of the liprin family in distinct aspects of tumor cell migration and invasion. Evidence from in vitro studies indicates that the widely expressed liprin-α1 protein regulates the migration and invasion of human breast cancer cells. Liprin-α1 affects cell migration and invasion by regulating the organization of lamellipodia and invadopodia, two structures relevant to cell invasion. In the cell liprin-α1 forms a complex with liprin-β1, ERC1/ELKS and LL5 proteins, which localizes at the front of migrating cells and positively regulates lamellipodia stability, and integrin–mediated focal adhesions. On the other hand, liprin-β2 appears to play a role as tumor suppressor by inhibiting breast cancer cell motility and invasion. The available data indicate that liprins are central players in the regulation of tumor cell invasion, therefore representing interesting targets for anti-metastatic therapy.
Keywords: Breast cancer, cell motility, focal adhesions, invasion, liprins.
Current Cancer Drug Targets
Title:Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Volume: 16 Issue: 3
Author(s): Sara Chiaretti and Ivan de Curtis
Affiliation:
Keywords: Breast cancer, cell motility, focal adhesions, invasion, liprins.
Abstract: Invasion leading to the formation of metastasis is one of the hallmarks of cancer. Analysis of different human cancers has led to the identification of the PPFIA1 gene encoding the protein liprin-α1, a possible player in cancer. The PPFIA1 gene is amplified in malignant tumors, including about 20% of breast cancers. Also the liprin-α1 protein is found overexpressed in tumors. Liprin-α1 belongs to the liprin family of cytosolic scaffold proteins that includes four liprin-α, two liprin-β members, and liprin-γ/kazrinE. In this review we will discuss the available evidence on the role of different members of the liprin family in distinct aspects of tumor cell migration and invasion. Evidence from in vitro studies indicates that the widely expressed liprin-α1 protein regulates the migration and invasion of human breast cancer cells. Liprin-α1 affects cell migration and invasion by regulating the organization of lamellipodia and invadopodia, two structures relevant to cell invasion. In the cell liprin-α1 forms a complex with liprin-β1, ERC1/ELKS and LL5 proteins, which localizes at the front of migrating cells and positively regulates lamellipodia stability, and integrin–mediated focal adhesions. On the other hand, liprin-β2 appears to play a role as tumor suppressor by inhibiting breast cancer cell motility and invasion. The available data indicate that liprins are central players in the regulation of tumor cell invasion, therefore representing interesting targets for anti-metastatic therapy.
Export Options
About this article
Cite this article as:
Chiaretti Sara and Curtis de Ivan, Role of Liprins in the Regulation of Tumor Cell Motility and Invasion, Current Cancer Drug Targets 2016; 16 (3) . https://dx.doi.org/10.2174/156800961603160206124103
DOI https://dx.doi.org/10.2174/156800961603160206124103 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The ErbB Receptors and Their Ligands in PKD, an Overview
Current Signal Transduction Therapy Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Bioactive Compounds in Some Culinary Aromatic Herbs and Their Effects on Human Health
Mini-Reviews in Medicinal Chemistry Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Polymersomes in Nanomedicine - A Review
Current Nanoscience Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Endothelial Cell Targeted Molecular Imaging in Tumor Angiogenesis: Strategies and Current Status
Current Pharmaceutical Biotechnology Reducing the Immunogenicity of Protein Therapeutics
Current Drug Targets Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Editorial (Thematic Issue: Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer)
Current Drug Targets Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer
Current Cancer Therapy Reviews Functional MRI of the Pancreaticobiliary System
Current Medical Imaging Immune Checkpoint Inhibitor Therapy and Risk of Myocarditis: A Review of the Literature
Current Immunology Reviews (Discontinued) The role of Nox-mediated oxidation in the regulation of cytoskeletal dynamics
Current Pharmaceutical Design Design, Synthesis and Antitumor Activities of Bis-arylureas and Bis-arylamides Based on1H-benzo[d]imidazole Moiety as Novel BRaf<sup>V600E</sup>/VEGFR2 Dual inhibitors
Letters in Drug Design & Discovery Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design